NeuroVive Pharmaceutical AB Year End Report January - December 2019
STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroVive compl...
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...
NeuroVive Pharmaceutical AB Interim Report January - September 2019
STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...
NeuroVive Pharmaceutical AB Interim Report January - June 2019
STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April - June * The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. * The Supreme Court delivers it...
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq
Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the
Annual report for 2018 is now available on the company's website
www.neurovive.com
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
LUND, Sweden, Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awardedSEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova,Sweden's innovation agency, and the Swelife call, for i...
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI
LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigat...
